US 11,951,100 B2
Formulations of RBP4 inhibitors and methods of use
Yu-Hsin Tom Lin, San Diego, CA (US); and Cheng-Chi Irene Wang, San Diego, CA (US)
Assigned to Belite Bio, LLC, San Diego, CA (US)
Filed by Belite Bio, LLC, San Diego, CA (US)
Filed on Sep. 1, 2023, as Appl. No. 18/460,080.
Application 18/460,080 is a continuation of application No. 17/620,427, previously published as PCT/US2020/040919, filed on Jul. 6, 2020.
Claims priority of provisional application 62/871,622, filed on Jul. 8, 2019.
Prior Publication US 2023/0404984 A1, Dec. 21, 2023
Int. Cl. A61K 31/437 (2006.01); A61K 9/10 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61P 27/02 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)
CPC A61K 31/437 (2013.01) [A61K 9/10 (2013.01); A61K 9/1635 (2013.01); A61K 9/1652 (2013.01); A61K 9/4866 (2013.01); A61P 27/02 (2018.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07B 2200/13 (2013.01)] 20 Claims
 
1. A polymorph of a compound of Formula (I) having the structure:

OG Complex Work Unit Chemistry
wherein the polymorph exhibits an X-ray powder diffraction (XRPD) pattern having at least three characteristic peaks expressed in degrees two theta (+/−0.5 degree theta) at 6.7, 9.3, 14.1, 17.2, 23.5, 27.1, and 29.0.